<DOC>
	<DOC>NCT02218034</DOC>
	<brief_summary>This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne vulgaris.</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Diagnosis of acne vulgaris on the face No tobacco use for the past 30 days, and willing to refrain from nicotine use during the study Willing to avoid excessive or prolonged exposure of the treated skin to ultraviolet light (eg, sunlight, tanning beds) and extremes in weather, such as wind or cold, throughout the study If male, willing to maintain routine shaving regimen for the duration of the study and avoid shaving 12 hours prior to specified visits Females of childbearing potential must use a reliable method of contraception Use of phototherapy devices (eg, ClearLight™) and adhesive cleansing strips (eg, Ponds® and Biore®), as well as cosmetic procedures (eg, facials, peeling, and comedone extraction) in the area to be treated in the past 1 week Use of topical antiinflammatory drugs, salicylic acid (eg, Clearasil® and Clean &amp; Clear®), corticosteroids, antibiotics, antibacterials (including benzoyl peroxidecontaining products [eg, benzamycin]), retinoids, and other topical acne treatments (eg, photodynamic therapy, laser therapy, and medicated soaps) in the area to be treated in the past 2 weeks Ability to abstain from caffeinecontaining products on the dates instructed</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>